New hope for rare bone cancer: targeted drugs enter early trial
NCT ID NCT07560410
First seen May 05, 2026 · Last updated Jun 23, 2026 · Updated 7 times
Summary
This early-phase trial will test two targeted drugs, crizotinib and alectinib, in 10 adults with a rare form of bone cancer that has a specific ALK gene change. Participants must have already tried standard treatments or have no standard options left. The goal is to see if these drugs can shrink tumors and control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BONE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China Medical University Hospital
Taichung, Taiwan
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
crizotinib (Xalkori) or alectinib (Alecensa)
What this could lead to
If successful, this could point toward a targeted treatment option for people with this rare bone cancer who have no other options.
What could go wrong
This is a very early, small trial with only 10 participants, so results may not apply widely. The drugs may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.